Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML

Table 2

The positive percentages of the expression among CD68, CD163, and CD206 in BMB samples of CML patients with different phases (percentage, mean ± SD).

Group	Cases	CD68	CD163	CD206	CD163/CD68 (%)	CD206/CD68 (%)
Control	30				21.90	23.73
CML-CP	30				73.68	76.62
CML-AP	21				83.63	86.40
CML-BP	15				89.23	91.83
Released CML-CP	30				44.37	45.77
Released CML-AP	15				66.84	66.90
Relapsed CML-AP	3				85.38	85.39
Released CML-BP	9				78.44	78.27
Relapsed CML-BP	4				85.71	85.71

(1) Data are expressed as percentage of positive staining. (2) Asterisks () indicate that the expression levels of CD68 did not exist statistically significant with respect to released patients with CML-AP group and CML-CP (). There was statistical significance among the other group and control group ().